Get the Stockscreener App
21.40
0.74%
-0.16
Pre-market:
20.41
-0.99
-4.63%
Ceribell Inc stock is traded at $21.40, with a volume of 140.39K.
It is down -0.74% in the last 24 hours and down -2.28% over the past month.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
See More
Previous Close:
$21.56
Open:
$21.71
24h Volume:
140.39K
Relative Volume:
0.61
Market Cap:
$767.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.69%
1M Performance:
-2.28%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$20.88
$21.92
1-Week Range:
$20.88
$23.27
52-Week Range:
$18.69
$32.75
Ceribell Inc Stock (CBLL) Company Profile
Name
Ceribell Inc
Sector
Industry
Phone
(800) 436-0826
Address
360 N. PASTORIA AVENUE, SUNNYVALE
Compare CBLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
21.40 | 767.58M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | BofA Securities | Buy |
| Nov-05-24 | Initiated | Canaccord Genuity | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Ceribell Inc Stock (CBLL) Latest News
CeriBell (NASDAQ:CBLL) Receives $32.60 Average PT from Analysts - Defense World
Rhumbline Advisers Makes New Investment in CeriBell (NASDAQ:CBLL) - Defense World
CeriBell’s Earnings Call: Strong Growth Amid Challenges - TipRanks
William Blair Estimates CeriBell’s Q1 Earnings (NASDAQ:CBLL) - Defense World
Canaccord Genuity Group Reaffirms Buy Rating for CeriBell (NASDAQ:CBLL) - Defense World
Ceribell revenue increases 41% to USD 18.5M in Q4 2024 - Medical Buyer
CeriBell, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Ceribell, Inc.: Strong Financial Performance and Strategic Investments Justify Buy Rating - TipRanks
Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating for Ceribell, Inc. - TipRanks
Ceribell, Inc. Reports Strong 2024 Financial Growth - TipRanks
Ceribell, Inc.: Strong Financial Performance and Growth Potential Drive Buy Rating - TipRanks
Earnings call transcript: CeriBell Q4 2024 shows 41% revenue growth - Investing.com
Earnings call transcript: CeriBell Q4 2024 shows 41% revenue growth By Investing.com - Investing.com UK
CeriBell Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ceribell, Inc. Reports Significant Revenue Growth in Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
CeriBell Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
CeriBell: A Leader In AI-Powered Seizure Detection (NASDAQ:CBLL) - Seeking Alpha
CeriBell (CBLL) to Release Earnings on Tuesday - MarketBeat
Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference - GlobeNewswire
CeriBell (NASDAQ:CBLL) Receives $32.60 Average Target Price from Analysts - MarketBeat
CeriBell (NASDAQ:CBLL) Receives $32.60 Average Price Target from Brokerages - Defense World
Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
CeriBell, Inc. to Announce Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
CeriBell (CBLL) Expected to Announce Quarterly Earnings on Tuesday - Defense World
CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Hospitals adopt AI tech to improve seizure detection in Humboldt County - KRCR
Nexalin Technology (NASDAQ:NXL) vs. CeriBell (NASDAQ:CBLL) Head-To-Head Contrast - Defense World
CeriBell (NASDAQ:CBLL) Trading 9.1% HigherShould You Buy? - MarketBeat
Beta Bionics targets up to $616 mln valuation in US IPO - Reuters
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus Price Target from Analysts - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) Price Target at $32.60 - MarketBeat
Ceribell Expands its Executive Management Team by Two - MPO-mag
CeriBell (NASDAQ:CBLL) Hits New 52-Week LowTime to Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Shares Down 9.2%Should You Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Trading Down 3.3%What's Next? - MarketBeat
Contrasting CeriBell (NASDAQ:CBLL) & Cutera (NASDAQ:CUTR) - Defense World
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus PT from Analysts - Defense World
Head to Head Contrast: CeriBell (NASDAQ:CBLL) & Vaso (OTCMKTS:VASO) - Defense World
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs - Marketscreener.com
CeriBell (NASDAQ:CBLL) Shares Down 2.6%Here's Why - MarketBeat
CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ceribell CEO to Present at J.P. Morgan Healthcare Conference 2025: Medical Tech Innovation in Focus - StockTitan
Ceribell Inc Stock (CBLL) Financials Data
There is no financial data for Ceribell Inc (CBLL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):